Production costs for synthetic methane in 2030 and 2050 of an optimized Power-to-Gas plant with intermediate hydrogen storage

The publication gives an overview of the production costs of synthetic methane in a Power-to-Gas process. The production costs depend in particularly on the electricity price and the full load hours of the plant sub-systems electrolysis and methanation. The full-load hours of electrolysis are given by the electricity supply concept. In order to increase the full-load hours of methanation, the size of the intermediate hydrogen storage tank and the size of the methanation are optimised on the basis of the availability of hydrogen. The calculation of the production costs for synthetic methane are done with economics for 2030 and 2050 and the expenditures are calculated for one year of operation. The sources of volume of purchased electricity are the short-term market, long-term contracts, direct-coupled renewable energy sources or seasonal use of surpluses. Gas sales are either traded on the short-term market or guaranteed by long-term contracts. The calculations show, that an intermediate storage tank for hydrogen, adjustment of the methanation size and operating electrolysis and methanation separately, increase the workload of the sub-system methanation. The gas production costs can be significantly reduced. With the future expected development of capital expenditures, operational expenditure, electricity prices, gas costs and efficiencies, an economic production of synthetic natural gas for the years 2030, especially for 2050, is feasible. The results show that Power-to-Gas is an option for long-term, large-scale seasonal storage of renewable energy. Especially the cases with high operating hours for the sub-system methanation and low electricity prices show gas production costs below the expected market prices for synthetic gas and biogas

Force and Motion Generation of Molecular Motors: A Generic Description

We review the properties of biological motor proteins which move along linear filaments that are polar and periodic. The physics of the operation of such motors can be described by simple stochastic models which are coupled to a chemical reaction. We analyze the essential features of force and motion generation and discuss the general properties of single motors in the framework of two-state models. Systems which contain large numbers of motors such as muscles and flagella motivate the study of many interacting motors within the framework of simple models. In this case, collective effects can lead to new types of behaviors such as dynamic instabilities of the steady states and oscillatory motion.Comment: 29 pages, 9 figure

Disorder Induced Diffusive Transport In Ratchets

The effects of quenched disorder on the overdamped motion of a driven particle on a periodic, asymmetric potential is studied. While for the unperturbed potential the transport is due to a regular drift, the quenched disorder induces a significant additional chaotic ``diffusive'' motion. The spatio-temporal evolution of the statistical ensemble is well described by a Gaussian distribution, implying a chaotic transport in the presence of quenched disorder.Comment: 10 pages, 4 EPS figures; submitted to Phys. Rev. Letter

Framework Report: The AIDS Accountability Workplace Scorecard, September 2011

The aim of the AIDS Accountability Workplace Scorecard is to improve HIV and AIDS workplace programmes in the countries and sectors most affected by the disease, and improve the health of employees, their families and communities. Through this initiative we will: / 1. Provide tools for HIV and AIDS workplace programme monitoring and evaluation AAI has developed scorecard tools for small, medium and large workplaces, which can be used to assess a global, regional or national HIV and AIDS programme or interventions at a specific workplace site. The scorecards can serve as both internal monitoring and evaluation tools and as assessments to present to stakeholders within and outside the organization. / 2. Publish annual Rankings of HIV and AIDS Workplace Programmes Scorecard users who wish to receive a ranking analysis and recommendations for how to improve their programmes can submit their scorecards to AAI. AAI ‘s ranking analysis will allow users to compare their performance with others and over time also measure their own progress. Respondents will be encouraged to publish their ranking in AAI’s yearly Ranking Reports. / 3. Share good practice The knowledge and good practices generated through the published rankings will be used to stimulate improved HIV and AIDS Workplace Programmes worldwide. Large networks of companies, trade union confederations, and national and international organizations can use the scorecard as a common framework for monitoring and evaluation of workplace programmes

Molecular motor that never steps backwards

We investigate the dynamics of a classical particle in a one-dimensional two-wave potential composed of two periodic potentials, that are time-independent and of the same amplitude and periodicity. One of the periodic potentials is externally driven and performs a translational motion with respect to the other. It is shown that if one of the potentials is of the ratchet type, translation of the potential in a given direction leads to motion of the particle in the same direction, whereas translation in the opposite direction leaves the particle localized at its original location. Moreover, even if the translation is random, but still has a finite velocity, an efficient directed transport of the particle occurs.Comment: 4 pages, 5 figures, Phys. Rev. Lett. (in print

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib

Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy. Bone marrow studies have shown that this residual disease resides within the stem cell compartment. Quiescence of leukemic stem cells has been suggested as a mechanism conferring insensitivity to imatinib, and exposure to the Granulocyte-Colony Stimulating Factor (G-CSF), together with imatinib, has led to a significant reduction in leukemic stem cells in vitro. In this paper, we design a novel mathematical model of stem cell quiescence to investigate the treatment response to imatinib and G-CSF. We find that the addition of G-CSF to an imatinib treatment protocol leads to observable effects only if the majority of leukemic stem cells are quiescent; otherwise it does not modulate the leukemic cell burden. The latter scenario is in agreement with clinical findings in a pilot study administering imatinib continuously or intermittently, with or without G-CSF (GIMI trial). Furthermore, our model predicts that the addition of G-CSF leads to a higher risk of resistance since it increases the production of cycling leukemic stem cells. Although the pilot study did not include enough patients to draw any conclusion with statistical significance, there were more cases of progression in the experimental arms as compared to continuous imatinib. Our results suggest that the additional use of G-CSF may be detrimental to patients in the clinic

Brownian motion exhibiting absolute negative mobility

We consider a single Brownian particle in a spatially symmetric, periodic system far from thermal equilibrium. This setup can be readily realized experimentally. Upon application of an external static force F, the average particle velocity is negative for F>0 and positive for F<0 (absolute negative mobility).Comment: 4 pages, 3 figures, to be published in PR

Epigenetic studies in children at risk of stunting and their parents in India, Indonesia and Senegal : A UKRI GCRF Action Against Stunting Hub protocol paper

ASR provided research and organisational support within the Action Against Stunting Hub (AASH) epigenetics theme and drafted and revised the manuscript. MN led the AASH epigenetic theme in Senegal and oversees the implementation of the epigenetic protocol and contributed to the development of the protocol and critically revised the manuscript. RRK led the AASH epigenetic theme in India and oversaw the implementation of the epigenetic protocol, contributed to the development of the protocol and critically revised the manuscript. MKH led the AASH epigenetic theme in Indonesia and oversaw the implementation of the epigenetic protocol, contributed to the development of the protocol and critically revised the manuscript. DYD was responsible for monitoring evaluation and learning on the hub, critically reviewed the protocol and revised the manuscript. LFA managed the implementation of the study in India, critically reviewed the protocol and revised the manuscript. NLZ managed the implementation of the study in Indonesia, critically reviewed the protocol and revised the manuscript. AD managed the implementation of the study in Senegal, critically reviewed the protocol and revised the manuscript. DY, TCA and MN are epigenetic researchers in Indonesia, critically reviewed the protocol and reviewed the manuscript. MG, DS, SSV and MM are epigenetic researchers in India, critically reviewed the protocol and reviewed the manuscript. GWH advised on the statistical aspects of the protocol and the power calculation and reviewed the manuscript. UF is the AASH project lead in Indonesia, contributed to study design and coordination of the study and thematic linkages; supervised drafting of the manuscript. BF is the AASH project lead in Senegal, contributed to study design and coordination of the study and thematic linkages and supervised drafting of the manuscript. BK is the AASH project lead in India, contributed to study design and coordination of the study and thematic linkages and supervised drafting of the manuscript. PH is the AASH project deputy lead and epigenetic theme lead who designed the study, drafted and revised the manuscript, carried out the statistical calculations.Peer reviewe

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

<p>Abstract</p> <p>Background</p> <p>Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.</p> <p>Methods</p> <p>Here, we introduce an analogue of CHS-828 called TP201565 with increased potency in cellular assays. Further, we describe and characterize a panel of cell lines with acquired stable resistance towards several NAMPT inhibitors of 18 to 20,000 fold compared to their parental cell lines.</p> <p>Results</p> <p>We find that 4 out of 5 of the resistant sublines display mutations of NAMPT located in the vicinity of the active site or in the dimer interface of NAMPT. Furthermore, we show that these mutations are responsible for the resistance observed. All the resistant cell lines formed xenograft tumours <it>in vivo</it>. Also, we confirm CHS-828 and TP201565 as competitive inhibitors of NAMPT through docking studies and by NAMPT precipitation from cellular lysate by an analogue of TP201565 linked to sepharose. The NAMPT precipitation could be inhibited by addition of APO866.</p> <p>Conclusion</p> <p>We found that CHS-828 and TP201565 are competitive inhibitors of NAMPT and that acquired resistance towards NAMPT inhibitors can be expected primarily to be caused by mutations in NAMPT.</p